Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025

Reuters

Oct 20

Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025

Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate $(ADC)$, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576000644"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576000644\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576000644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576000644","market":"nz","top_or_hot":-1,"title":"Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06996","symbol_name":"德琪医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL8yfGk1:1","article_id":"2576000644","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576000644","pubTimestamp":1760922025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate , in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025  in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06996":"德琪医药-B","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"德琪医药在ESMO 2025上报告ATG-022治疗胃癌的I/II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":0.9},"content_text":"Antengene Reports Promising ATG-022 Phase I/II Results in Gastric Cancer at ESMO 2025\n    \n\n        Antengene Corporation Ltd. has announced new clinical data from the ongoing Phase I/II CLINCH study of ATG-022, a Claudin 18.2 antibody-drug conjugate $(ADC)$, in patients with advanced gastric and gastroesophageal junction cancer. The results were presented in a poster session at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin. The study demonstrated efficacy across all CLDN18.2 expression levels, with three complete responses observed across different dose cohorts, including those with low or ultra-low CLDN18.2 expression. Safety data from the 2.4 mg/kg cohort indicated a favorable profile, with the lower 1.8 mg/kg cohort showing even better tolerability. ATG-022 has received two Orphan Drug designations from the U.S. FDA and Breakthrough Therapy Designation from China's NMPA for specific gastric cancer indications. Dose expansion studies are ongoing in China and Australia, with preparations underway for combination therapy trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN01587) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}